Lindeboom R, De Haan R, Aramideh M, Speelman J D
Department of Neurology, Academic Medical Centre, University of Amsterdam, The Netherlands.
Mov Disord. 1995 Jul;10(4):444-9. doi: 10.1002/mds.870100407.
Assessment of the functional status in patients with blepharospasm is of major importance for clinical practice and outcome studies. The Blepharospasm Disability Scale (BDS) is specifically directed to measure the disability in these patients. The metric properties of this instrument were evaluated. Reliability, validity, and responsiveness to within-patient health changes over time of the BDS were assessed in 40 patients with essential blepharospasm treated with botulinum toxin injections. The reliability of the scale was sufficient for use on group level (Cronbach's alpha coefficient, 0.69). Evidence of discriminant validity was provided by the difference in median score on the BDS between 21 newly admitted patients and 19 patients already under treatment (p < 0.001). Convergent validity was supported by correlations between BDS and neurological impairment scores (range, Spearman correlation coefficients, 0.65-0.79). Responsiveness to health changes was demonstrated by a significant difference between median BDS scores before treatment and 2 weeks after treatment with botulinum toxin (p < 0.01). The BDS is a useful disease-specific instrument to assess disability. Completion of the questionnaire is easy and takes only a few minutes. The instrument is suitable for use in patient care, descriptive outcome studies, and should be considered in controlled clinical trials.
评估眼睑痉挛患者的功能状态对临床实践和疗效研究至关重要。眼睑痉挛残疾量表（BDS）专门用于测量这些患者的残疾程度。对该工具的度量特性进行了评估。在40例接受肉毒杆菌毒素注射治疗的原发性眼睑痉挛患者中，评估了BDS的信度、效度以及对患者健康随时间变化的反应性。该量表在组水平上的信度足以使用（克朗巴赫α系数为0.69）。21例新入院患者和19例已接受治疗患者的BDS中位数得分差异提供了区分效度的证据（p < 0.001）。BDS与神经功能损害评分之间的相关性支持了聚合效度（范围，斯皮尔曼相关系数为0.65 - 0.79）。治疗前与肉毒杆菌毒素治疗2周后的BDS中位数得分存在显著差异，证明了对健康变化的反应性（p < 0.01）。BDS是一种有用的针对特定疾病的评估残疾的工具。完成问卷很容易，只需几分钟。该工具适用于患者护理、描述性疗效研究，在对照临床试验中也应予以考虑。
